Equity Overview
Price & Market Data
Price: $0.629
Daily Change: +$0.0094 / 1.49%
Daily Range: $0.61 - $0.67
Market Cap: $151,455,273
Daily Volume: 227,288
Performance Metrics
1 Week: 1.52%
1 Month: -11.35%
3 Months: 46.41%
6 Months: 78.55%
1 Year: 87.88%
YTD: 82.43%
Company Details
Employees: 74
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.